Aims and Scope
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.
Types of Papers:
Full length Research Papers of original experimental or clinical research: max. 6500 words (including tables and legends to figures) and no more than 80 references; Short Communications: max 2500 words and no more than 25 references; Reviews on specialised topics: no word limit, no more than 150 references. Letters to the Editor can be related or not to material published in the journal but are limited to 500 words and 5 references.
A total word-count should be submitted together with your manuscript.
Submission of Manuscripts
The submission to and peer review process of European Neuropsychopharmacology proceeds totally online. To submit your article, please visit http://ees.elsevier.com/eurneuropsychopharmacol and you will be guided stepwise through the creation and uploading of the various files. Once the uploading is done, the system automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence, including the Editor's decision and request for revisions, will be processed through the system and will reach the corresponding author by e-mail.
Authors may send queries concerning the submission process or journal procedures to the Editor-in-Chief:Andreas Meyer-Lindenberg MD
Director, Central Institute of Menatl Health
Department of Psychiatry and Psychotherapy
University of Heidelberg, Medical Faculty Mannheim
Article transfer serviceThis journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information about this can be found here: http://www.elsevier.com/authors/article-transfer-service.
Organisation of the Manuscript
Only submissions in English will be considered. The title page should include: the title, the name(s) and affiliation(s) of the author(s), and address for correspondence, and telephone numbers for editorial queries.
The text should be ordered under the following headings: 1. Introduction, 2. Experimental procedures, 3. Results, 4. Discussion, Author Disclosures (see separete section on this), References.HIGHLIGHTS
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See http://www.elsevier.com/highlights for examples.NEW - Supplementary data
European Neuropsychopharmacology now also accepts electronic supplementary material (e-components) to support and enhance presentation of your scientific research. Supplementary files offer the Author additional possibilities to publish supporting applications, movies, animation sequences,high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submittedmaterial is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
At their discretion authors are also invited to submit 5-15 Power Point slides summarizing in words, tables or figures their paper. The slides will be posted on the journal site and readers will have the opportunity to download and use the slides for didactical purposes only.
Please use the template provided to format your content.
Please note also that the slides will appear online exactly as they are submitted without further type-setting.
Role of Funding Source. Authors are kindly requested to briefly describe the role of the study sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement, authors should so state.
eg, Funding for this study was provided by NIMH Grant XXXXXXX; the NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.Following the Role of the Funding Source text, authors are required to declare their individual contribution to the manuscript under a subheading Contributors.
eg, Author X designed the study and wrote the protocol. Author Y managed the literature searches and analyses. Authors X and Z undertook the statistical analysis, and author W wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.The third aspect of the Journal's new policy concerns the Conflict of Interest. ALL authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three (3) years of beginning the work submitted that could inappropriately influence, or be perceived to influence, their work.
Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership (except for personal investment purposes equal to the lesser of one percent (1%) or USD 5000), honoraria, paid expert testimony, patent applications, registrations, and grants. If there are no conflicts of interest, authors should state that there are none.eg, Author Y owns shares in pharma company A. Author X and Z have consulted for pharma company B. All other authors declare that they have no conflicts of interest.
Finally, before the references, the Journal will publish Acknowledgements, in a separate section, and not as a footnote on the title page.eg, We thank Mr A, who kindly provided the data necessary for our analysis, and Miss B, who assisted with the preparation and proof-reading of the manuscript.
NB. During the online submission process the author will be prompted to upload these four mandatory author disclosures as separate items. They will be automatically incorporated in the PDF builder of the online submission system. Please do not include in the main manuscripts.
Papers that do not conform to the general criteria for publication in European Neuropsychopharmacology will be returned immediately to authors to avoid unnecessary delay in submission elsewhere.Figures and Photographs
Figures and Photographs of good quality should be submitted online as a separate file. Please use a lettering that remains clearly readable even after reduction to about 66%. For every figure or photograph, a legend should be provided. All authors wishing to use illustrations already published must first obtain the permission of the author and publisher and/or copyright holders and give precise reference to the original work. This permission must include the right to publish in electronic media.
Tables should be numbered consecutively with Arabic numerals and must be cited in the text in sequence. Each table, with an appropriate brief legend, comprehensible without reference to the text, should be typed on a separate page and uploaded online. Tables should be kept as simple as possible and wherever possible a graphical representation used instead. Table titles should be complete but brief. Information other than that defining the data should be presented as footnotes.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article.
Authors are responsible for the accuracy of the references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the text.
All citations in the text should refer to:
Two authors: both authors'names and the year of publication;
Three or more authors: first author's name followed by "el al." and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.Examples: "as demonstrated (Allan, 1996a, 1996b, 1999; Allan and Jones, 1995). Kramer et al. (2000) have recently shown ...."
References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters "a", "b", "c", etc., placed after the year of publication.
Reference to a journal publication:
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2000. The art of writing a scientific article. J. Sci. Commun. 163, 51-59.
Reference to a book:
Strunk Jr., W., White, E.B., 1979. The Elements of Style, third ed. Macmillan, New York.
Mettam, G.R., Adams, L.B., 1999. How to prepare an electronic version of your article, in: Jones, B.S., Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281-304.
Reference to a dataset:
Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. Mendeley Data, v1. http://dx.doi.org/10.17632/xwj98nb39r.1.
Metric units must be used throughout; laboratory units must be followed by SI (Systeme International) units. The generic name of the drug should be used unless the specific trade name of the drug is directly relevant to the discussion. For receptor nomenclature, authors are referred to the special supplement of Trends in Pharmacological Sciences devoted to this.Ethics of experimentation Procedures involving experiments on human subjects should be in accordance with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accordance with the Helsinki Declaration of 1975. Procedures involving experimentation on animals should be done in accordance with the guidelines of the institution in which the experiments were done.
Neuroscience-based Nomenclature (NbN)
European Neuropsychopharmacology requires the use of Neuroscience-based Nomenclature (NbN) terminology for psychotropic medications, as it reflects contemporary pharmacological knowledge, rather than arbitrary descriptors based on indications or chemical structure. Please download the free app for correct use of NbN terminology (http://nbnomenclature.org/). An overview of the Glossary is below (NbN Glossary). While you are welcome to use NbN throughout the manuscript, as a minimum requirement we ask that on first mention in the paper, substances are referred to by their NbN classification and that all substances studied in the paper receive NbN compliant keywords.
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. Polaroid colour prints are not suitable.
If, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the Web (e.g. ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for colour in print or on the Web only. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artwork.
Please note: Because of technical complications which can arise by converting colour figures to "grey scale" (for the printed version should younot opt for colour in print) please submit in addition usable black and white versions of all the colour illustrations.Copyright Transfer
Upon acceptance of an article, you will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. If excerpts from other copyrighted works are included in the submission, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights Department, Philadelphia, PA, USA: phone (+1) 215 238 7869, fax (+1) 215 238 2239, e-mail email@example.com. Requests for materials from other Elsevier publications may also be completed on-line via the Elsevier homepage http://www.elsevier.com/locate/permissions.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Procedures involving experiments on human subjects should be in accordance with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accordance with the Helsinki Declaration of 1975. Procedures involving experimentation on animals should be done in accordance with the guidelines of the institution in which the experiments were done.
One set of proofs will be supplied to the author to check for type-setting accuracy: no changes to the manuscript will be allowed at this stage. Elsevier will do everything possible to correct your article and publish it accurately and without delay. It is important, therefore, to ensure that all author corrections are marked clearly on your proofs and returned to us in one communication. No additional corrections are possible following receipt by Elsevier of the first set of marked up proofs. In the interests of publication time, authors should respond as quickly as possible, preferably by e-mail.
PDF offprints are provided free of charge. No reprints are provided free of charge. Reprints (50 copies minimum) can be ordered at quoted prices on order forms sent out together with the proofs.